

SECTOR

Biotechnology

Analysis and Synthesis - World




January 8, **2019**



Biotechnology (WO)

Closing price of January 8, 2019

Comparison [January 9, 2018 - January 8, 2019]



The sector Biotechnology represents approximately 15% of the market capitalization of the group Health Care and approximately 1% of the World market with 130 companies being regularly followed by the Screener.

The sector Biotechnology is currently trading 6% below its 52 week high and 18% above its 52 week low (bi-weekly closing).

Performance since January 9, 2018: 10.4% vs. 4.7% for the group Health Care and -10.0% for the TSC_World.

The current % of stocks over their Medium Term technical trend (MTT) is 53.1%.

| | Market Value | Perf YtD | Nb of Stocks | Mkt Cap in \$bn | Stars | Sensitivity | G/PE Ratio | LT P/E | LT Growth | 4wk Perf | % of Stocks in Uptrend |
|---------------------------|--------------|----------|--------------|-----------------|-------|-------------|------------|--------|-----------|----------|------------------------|
| Biotechnology (WO) | 800.69 | 9.2% | 130 | 818.39 | ★★★★★ | 📈 | 0.86 | 20.1 | 16.3% | 5.7% | 53.1% |
| Health Care (WO) | 220.99 | 1.6% | 471 | 6,034.88 | ★★★★★ | 📈 | 0.99 | 15.2 | 13.1% | -1.6% | 31.6% |
| TSC_World (WO) | 271.85 | 2.1% | 5,879 | 64,631.40 | ★★★★★ | 📈 | 1.21 | 11.8 | 11.2% | -1.0% | 32.2% |

Price evaluation rating


In order to assess whether an index is correctly valued, we focus on Peter Lynch's broadly accepted methodology of comparing the projected earnings growth and dividend with the estimated PE ratio. Based on this approach, we feel this sector is currently fairly valued. A "Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings" ratio below 0.9 indicates that investors must pay a premium for the estimated growth potential: 4.9% premium.

"Price to Estimated Earnings" (PE) - Evolution over five years



The estimated PE is calculated on the basis of the underlying stocks. While the PE of the sector Biotechnology is 20.1, the PE of the group to which it belongs (Health Care is markedly lower (15.2); this indicates that the sector is trading higher than its group. Historically speaking, this sector is currently trading significantly higher than its median of 15.0.

Earnings revision trend



Compared to seven weeks ago, the analysts have lowered (-3.8%) their earnings estimates. This negative pressure began November 6, 2018 at a price of 779.2.

Technical trend

The 40-day Medium Term Technical Trend has been positive since January 4, 2019. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is currently 8% lower. This positive technical trend is confirmed by the fact that 53.1% percent of stocks are trading above their average. This would indicate that a significant number of stocks in this sector are part of the current market rise.

Comparison [January 10, 2014 - January 8, 2019]



Performance over 5 years

On a 5 year moving average, the performance of the sector Biotechnology is 93.1%, vs. 52.0% for the group Health Care and 27.3% for the TSC_World. During this period, the high of 853.3 was reached on September 2018 and the low of 381.9 in the month of April 2014.




Biotechnology (WO)

Closing price of January 8, 2019

| | Market Value | Perf YtD | Nb of Stocks | Mkt Cap in \$bn | Stars | Sensitivity | G/PE Ratio | LT P/E | LT Growth | 4wk Perf | % of Stocks in Uptrend |
|--------------------|--------------|----------|--------------|-----------------|-------|-------------|------------|--------|-----------|----------|------------------------|
| Biotechnology (WO) | 800.69 | 9.2% | 130 | 818.39 | ★★★★★ | | 0.86 | 20.1 | 16.3% | 5.7% | 53.1% |

Volatility



The volatility is also used as a sensitivity factor. It measures the magnitude of the upward and downward movements of a stock or index. The higher the volatility, the more sensitive a sector is considered to be.

As of the last update, the monthly volatility of (38.5%) is higher than the last few years' average of (20.1%). The high magnitude of short term price fluctuations indicates the market is very nervous.

On the other hand, long term volatility 20.7% of the sector is clearly higher than that of the group Health Care (15.3%), reflecting much higher price variations at the sector level than at the level of the group to which it belongs.

Sensitivity factor in declining markets

The "Bear Market Factor" measures the behavior of a sector in declining markets. In this context, the sector Biotechnology has a tendency to drop in the same proportion as the index TSC_World.

The sector shows average sensitive reactions to market corrections.

Sensitivity factor in rising markets

The "Bad News Factor" measures a sector's corrections in a rising market phase.

In this configuration, the market slightly sanctions the sector Biotechnology when there is specific pressure in this particular economic activity.

When the sector declines in a rising market its average deviation is -1.05%.


Sensitivity analysis summary

Generally speaking, the Biotechnology sector shows an average sensitive behaviour with an average Bear Market and a low Bad News factor.

Checklist (Biotechnology)


| | | |
|--------------------|--------|---|
| Stars | ★★★★★ | Strong interest since January 4, 2019. |
| Earnings Rev Trend | ★ | Analysts negative since November 6, 2018 |
| Valuation Rating | ★ | Fairly priced |
| MT Tech Trend | ★ | Market positive since January 4, 2019 |
| 4wk Rel Perf | 5.7% ★ | vs. TSC_World |
| Sensitivity | | The industry has been on the moderate-sensitivity level since December 25, 2018. |
| Bear Mkt Factor | | Average sensitivity to market corrections |
| Bad News Factor | | Slight market sanction in case of specific pressure |

Allocation by sector, of the group Health Care



The largest sector in terms of market capitalization Pharmaceuticals represents 49.8% of the group Health Care. These sectors follow, in size order, Medical Equipment with 23.5% Biotechnology with 13.6%.

2019 sector evolution



From the beginning of the year, the sector Biotechnology recorded a variation of 9.2%, while the group Health Care evolved by 1.6%. This industry group is made up of 5 sectors, in which the extreme variations were from -1.2% to 9.2%.




Biotechnology (WO)


Closing price of January 8, 2019

| | Market Value | Perf YtD | Nb of Stocks | Mkt Cap in \$bn | Stars | Sensitivity | G/PE Ratio | LT P/E | LT Growth | 4wk Perf | % of Stocks in Uptrend |
|--------------------|--------------|----------|--------------|-----------------|-------|-------------|------------|--------|-----------|----------|------------------------|
| Biotechnology (WO) | 800.69 | 9.2% | 130 | 818.39 | ★★★★☆ | | 0.86 | 20.1 | 16.3% | 5.7% | 53.1% |

The performance of the 20 largest stocks of the sector is presented below.




The analysis and details of the above stock can be found on page 6




The analysis and details of the above stock can be found on page 6

Top Stocks 2019



From the beginning of the year, the performance of the sector was 9.2%; as for the three best stocks, (INSMED INCO. (INSM), LOXO ONCOLOGY (LOXO) and EPIZYME (EPZM)), their performance was 65.9%, 65.8% and 47.4% respectively.


Flop Stocks 2019



HUALAN BIOLOGICAL ENGR. (002007), CELLTRION INCORPORATED (A068270) and MEDY TOX INCO. (A086900) with -4.2%, -4.0% and -3.5% recorded the three worst performances from the beginning of the year. For the sector Biotechnology, the variation was 9.2%.


Only companies with a market capitalization exceeding \$500 million are mentioned.

Top Stocks 12 months



Since 12 months ago, the performance of the sector has been 10.4%; the three best stocks, (AMARIN CORP.PL. (AMRN), PACIFIC BSCS.OF CAL.INCO (PACB) and INTERCEPT PHARMS.INCO. (ICPT)) recorded a performances of 223.5%, 170.0% and 107.5% respectively.

Flop Stocks 12 months



The three worst performances in 12 months were recorded by PUMA BIOTECHNOLOGY INCO. (PBYI), INDIVIOR PLC. (INDV) and CLOVIS ONCOLOGY INCO. (CLVS) with -74.1%, -70.2% and -61.5%. As for the sector Biotechnology, it recorded a variation of 10.4%.




Biotechnology (WO)


Closing price of January 8, 2019

Stocks with the best valuations

| Symbol Market | Name Sector | Price Ccy | Mkt Cap in \$bn | 7wk EPS Rev | Stars | Sensitivity | Global Evaluation |
|---------------|-------------------------------------|--------------|-----------------|-------------|-------|-------------|-------------------|
| HZNP US | HORIZON PHARMA PLC. Biotechnology | 21.36 USD | 3.58 | 9.5% | ★★★★★ | Low | High |
| IONS US | IONIS PHARMS.INCO. Biotechnology | 57.20 USD | 7.87 | 70.9% | ★★★★★ | Low | High |
| ARRY US | ARRAY BIOPHARMA INCO. Biotechnology | 17.55 USD | 3.74 | 46.5% | ★★★★★ | Low | High |
| LOXO US | LOXO ONCOLOGY Biotechnology | 232.29 USD | 7.11 | 14.4% | ★★★★★ | Low | High |
| ABC GB | ABCAM PLC. Biotechnology | 1,203.00 GBp | 3.15 | 12.2% | ★★★★★ | Low | High |



The global rating (Global Evaluation) is a multi-criteria approach that identifies the stocks with the best valuations. This assessment is the compilation of fundamental (PE, growth, earnings revisions, dividend, etc.), technical (moving average, relative performance), and sensitivity (behaviour in declining markets and sensitivity to bad news) factors. In order to present the best selection, only companies with a market capitalization greater than \$1bn and showing good earnings growth valuations, are listed. Furthermore, the eligible stocks must have a minimum rating of two stars, a neutral to positive valuation, and a low to moderate sensitivity. When the global rankings are identical, the analysts' 7 week earnings per share revision (7 wk EPS rev) acts as the deciding classification element.




The best defensive stocks

| Symbol Market | Name Sector | Price Ccy | Mkt Cap in \$bn | Bear Mkt Factor | Stars | Sensitivity | Global Evaluation |
|---------------|---------------------------------------|--------------|-----------------|-----------------|-------|-------------|-------------------|
| HZNP US | HORIZON PHARMA PLC. Biotechnology | 21.36 USD | 3.58 | -90 | ★★★★★ | Low | High |
| ASND US | ASCENDIS PHARMA Biotechnology | 70.94 USD | 2.98 | -75 | ★★★★★ | Low | High |
| 002007 CN | HUALAN BIOLOGICAL ENGR. Biotechnology | 31.41 CNY | 4.26 | -67 | ★★★★★ | Low | High |
| ABC GB | ABCAM PLC. Biotechnology | 1,203.00 GBp | 3.15 | -59 | ★★★★★ | Low | High |
| ARGX BE | ARGENX SE Biotechnology | 98.40 EUR | 4.04 | -98 | ★★★★★ | Low | High |

The sensitivity assessment is essentially based on two criteria: the stock's "behaviour in declining markets" (Bear Market Factor), and the stock's "sensitivity to bad news" (Bad News Factor). By positioning a stock according to the world averages, three sensitivity levels can be attributed (low, moderate, high). Combining these elements makes it possible to create a final ranking of stocks in the market. To present the most useful selection, only companies with a market capitalization greater than \$1bn and showing good earnings growth valuations are listed. Furthermore, the eligible stocks must have a minimum rating of two stars, a neutral to positive valuation, and a low to moderate sensitivity. In case of a tie, the stock's "behaviour in declining markets" will act as the deciding classification element.

The stocks with the lowest correlations

| Symbol Market | Name Sector | Price Ccy | Mkt Cap in \$bn | Correlation | Stars | Sensitivity | Global Evaluation |
|---------------|--|----------------|-----------------|-------------|-------|-------------|-------------------|
| ARNA US | ARENA PHARMS.INCO. Biotechnology | 43.27 USD | 2.14 | 0.18 | ★★★★★ | Low | High |
| CBPO US | CHIN.BIOLOGIC PRDS.HDG. Biotechnology | 77.47 USD | 3.05 | 0.23 | ★★★★★ | Low | High |
| ARGX BE | ARGENX SE Biotechnology | 98.40 EUR | 4.04 | 0.23 | ★★★★★ | Low | High |
| PACB US | PACIFIC BSCS.OF CAL.INCO Biotechnology | 7.37 USD | 1.10 | 0.26 | ★★★★★ | Low | High |
| A086900 KR | MEDY TOX INCO. Biotechnology | 557,400.00 KRW | 2.88 | 0.30 | ★★★★★ | Low | High |




The correlation coefficient permits to identify the stocks whose dependence on the market is the weakest. If this value is very low, less than 0.5, it means that less than 50% of the movements of the stock are explained by market movements. On the contrary, a number close to 1 indicates that the value is very close to the evolutions of the market. In order to present the best selection, only companies with a market capitalization higher than \$1bn and showing good earnings growth valuations are listed. Furthermore, the eligible stocks must have a minimum rating of two stars, a neutral to positive valuation, a low to moderate sensitivity, and a correlation of maximum 0.66. In the case of a tie in the ranking, the stock's correlation in ascending order acts as the deciding classification element.



Biotechnology (WO)

Closing price of January 8, 2019



The stocks with the lowest PE

| Symbol Market | Name Sector | Price Ccy | Mkt Cap in \$bn | LT P/E | Stars | Sensitivity | Global Evaluation |
|---------------|-------------------------------------|------------|-----------------|--------|-------|-------------|-------------------|
| HZNP US | HORIZON PHARMA PLC. Biotechnology | 21.36 USD | 3.58 | 9.1 | ★★★★ | 📈 | 📊 |
| ARRY US | ARRAY BIOPHARMA INCO. Biotechnology | 17.55 USD | 3.74 | 9.2 | ★★★★ | 📈 | 📊 |
| GILD US | GILEAD SCIENCES INCO. Biotechnology | 68.09 USD | 88.08 | 9.7 | ★★★★ | 📈 | 📊 |
| SYNH US | SYNEOS HEALTH INCO. Biotechnology | 45.00 USD | 5.12 | 12.6 | ★★★★ | 📈 | 📊 |
| AMGN US | AMGEN INCO. Biotechnology | 200.61 USD | 127.83 | 12.8 | ★★★★ | 📈 | 📊 |

The price to earnings ratio (PE) helps to find undervalued stocks. It is commonly accepted that if the PE of a stock is lower than the PE of its reference market, the stock may have upside potential. In order to present the best selection, only companies with a market capitalization greater than \$1bn and showing good earnings growth valuations are listed. Furthermore, the eligible stocks must have: a minimum rating of two stars, a neutral to positive valuation, and a low to moderate sensitivity. When the PE ratios are identical, the analysts' 7 week earnings per share revision (7 wk EPS rev) acts as the deciding classification element.

The 20 top stocks classified by market capitalization

| Symbol Market | Name Sector | Price Ccy | Perf YtD | Mkt Cap in \$bn | G/PE Ratio | LT P/E | LT Growth | 4wk Rel Perf | Div | Volatility 1M | Stars | Sensitivity | Global Evaluation |
|---------------|--------------------------------------|----------------|----------|-----------------|------------|--------|-----------|--------------|------|---------------|-------|-------------|-------------------|
| AMGN US | AMGEN INCO. Biotechnology | 200.61 USD | 3.1% | 127.83 | 0.84 | 12.8 | 8.0% | 7.0% | 2.8% | 34.8% | ★★★★ | 📈 | 📊 |
| GILD US | GILEAD SCIENCES INCO. Biotechnology | 68.09 USD | 8.9% | 88.08 | 0.91 | 9.7 | 5.1% | 2.1% | 3.7% | 41.7% | ★★★★ | 📈 | 📊 |
| BIIB US | BIOGEN INCO. Biotechnology | 324.44 USD | 7.8% | 65.37 | 0.69 | 10.9 | 7.5% | 4.7% | 0.0% | 45.4% | ★★★★ | 📈 | 📊 |
| VRTX US | VERTEX PHARMS.INCO. Biotechnology | 178.19 USD | 7.5% | 45.54 | 0.92 | 32.5 | 29.7% | 5.7% | 0.0% | 41.6% | ★★★★ | 📈 | 📊 |
| ILMN US | ILLUMINA INCO. Biotechnology | 293.75 USD | -2.1% | 43.18 | 0.68 | 38.0 | 25.9% | -6.4% | 0.0% | 59.2% | ★★★★ | 📈 | 📊 |
| REGN US | REGENERON PHARMS.INCO. Biotechnology | 397.26 USD | 6.4% | 43.00 | 0.76 | 14.5 | 11.1% | 8.8% | 0.0% | 46.2% | ★★★★ | 📈 | 📊 |
| A068270 KR | CELLTRION INCORPORATED Biotechnology | 213,500.00 KRW | -4.0% | 24.30 | 0.86 | 54.4 | 46.7% | -7.7% | 0.0% | 49.7% | ★★★★ | 📈 | 📊 |
| ALXN US | ALEXION PHARMS.INCO. Biotechnology | 108.61 USD | 11.6% | 24.23 | 1.24 | 9.6 | 11.9% | -3.8% | 0.0% | 60.8% | ★★★★ | 📈 | 📊 |
| GRF ES | GRIFOLS SA Biotechnology | 23.90 EUR | 4.4% | 16.69 | 0.93 | 18.7 | 15.6% | -2.2% | 1.8% | 20.0% | ★★★★ | 📈 | 📊 |
| BMRN US | BIOMARIN PHARM.INCO. Biotechnology | 92.30 USD | 8.4% | 16.44 | 13.04 | 31.5 | 410.8% | 1.8% | 0.0% | 51.7% | ★★★★ | 📈 | 📊 |
| BGNE US | BEIGENE LTD. Biotechnology | 139.53 USD | -0.5% | 16.12 | -0.20 | -21.9 | -4.3% | 3.6% | 0.0% | 71.2% | ★★★★ | 📈 | 📊 |
| INCY US | INCYTE CORP. Biotechnology | 74.90 USD | 17.8% | 15.94 | 1.95 | 18.9 | 37.0% | 18.3% | 0.0% | 65.8% | ★★★★ | 📈 | 📊 |
| SGEN US | SEATTLE GENETC.INCO. Biotechnology | 67.23 USD | 18.7% | 10.85 | 1.31 | 67.2 | 87.9% | 14.3% | 0.0% | 66.9% | ★★★★ | 📈 | 📊 |
| GEN DK | GENMAB A/S Biotechnology | 1,100.50 DKK | 3.1% | 10.37 | 1.36 | 23.2 | 31.4% | 10.2% | 0.0% | 27.7% | ★★★★ | 📈 | 📊 |
| EXAS US | EXACT SCIS.CORP. Biotechnology | 76.16 USD | 20.7% | 9.36 | -0.45 | -515.2 | -231.6% | 8.5% | 0.0% | 99.0% | ★★★★ | 📈 | 📊 |
| ALNY US | ALNYLAM PHARMS.INCO. Biotechnology | 85.34 USD | 17.0% | 8.62 | 0.66 | 155.8 | 103.0% | 17.0% | 0.0% | 88.5% | ★★★★ | 📈 | 📊 |
| QIA DE | QIAGEN NV Biotechnology | 30.51 EUR | 3.6% | 8.06 | 0.84 | 20.2 | 16.9% | -1.3% | 0.0% | 22.9% | ★★★★ | 📈 | 📊 |
| IONS US | IONIS PHARMS.INCO. Biotechnology | 57.20 USD | 5.8% | 7.87 | 2.32 | 30.0 | 69.5% | 9.9% | 0.0% | 39.1% | ★★★★ | 📈 | 📊 |
| NBIX US | NEUROCRINE BSCS.INCO. Biotechnology | 84.42 USD | 18.2% | 7.66 | 11.20 | 18.1 | 202.9% | 2.5% | 0.0% | 89.2% | ★★★★ | 📈 | 📊 |
| LOXO US | LOXO ONCOLOGY Biotechnology | 232.29 USD | 65.8% | 7.11 | 1.21 | 37.7 | 45.4% | 74.3% | 0.0% | 186.6% | ★★★★ | 📈 | 📊 |

Number of Stocks

This is the number of stocks in the index that can be analyzed.

Mkt Cap in \$bn

This number represents the Market Capitalization in USD bn. It is calculated by multiplying a firm's share price by the number of outstanding shares. For reasons of comparison, all results are in USD.

Valuation Rating

Our Valuation Rating indicates if a stock is "expensive" or "cheap" relative to its growth potential. This is used to determine whether or not the investor is paying a premium for anticipated growth.

To estimate a stock's value relative to its current price, our Valuation Rating combines:

- stock price
- projected earnings
- projected earnings growth
- dividends

We establish our rating by combining these elements.

There are five ratings, ranging from strongly undervalued 🟢🟢 to strongly overvalued 🟡🔴.

Stars

theScreener.com's star rating system is designed to enable you to identify high-quality stocks quickly and easily.

In this easy-to-use rating system, stars are earned for each element specified below:

- Earnings Rev Trend 🟢 = ★★★★★
- Valuation Rating 🟢, 🟢🟢, 🟢🟢🟢 = ★★★★★
- MT Tech Trend 🟢 = ★★★★★
- 4 week Relative Performance > 1% = ★★★★★

Therefore, a stock can earn a maximum of four stars.

The lowest rating a stock can have is no stars.

Once a stock has earned a star, it will keep it until:

- Earnings Rev Trend becomes negative 🟡
- Valuation Rating becomes negative 🟡, 🟡🔴, 🟡🔴🔴
- MT Tech Trend becomes negative 🟡
- 4 week Relative Performance drops below -1% (<-1%)

Div

This is the dividend in % for the next 12 months.

Even if the same number is shown, the dividend value can appear in one of four colors, depending on the earnings coverage:

- 0%, no dividend
- 4%, the dividends are covered (between 0% and 40% of earnings)
- 4%, the dividends represent between 40% and 70% of earnings
- 4%, the dividends are higher than 70% of earnings, which implies that the dividend coverage is not guaranteed.

Earnings Rev. Trend

The symbol 🟢 shows that compared with their earnings revisions of seven weeks ago, the analysts have now raised their estimates (7wk EPS Rev; > 1%); the symbol 🟡 indicates that compared with their earnings revisions of seven weeks ago, the analysts have now lowered their estimates (7wk EPS Rev < -1%).

When the earnings revisions (7wk EPS Rev) fall between +1% and -1%, the trend is considered to be neutral 🟢.

The symbol 🟢 indicates that the last significant revisions have been trending positive.

The symbol 🟡 indicates that the last significant revisions have been negative.

7wk EPS Rev

This is an abbreviation for 7 week Earnings Per Share Revision. This column indicates the value of these revised earnings. A figure of 2.8 signifies that compared with seven weeks ago, the analysts have now revised and raised their estimates by 2.8%. On the contrary, a negative number means that the earnings would have been revised lower.

G/PE Ratio

In order to establish our Valuation Rating, we calculate the estimated growth of future earnings (LT Growth) plus dividend in %, divided by the estimated future PE ratio (Long Term P/E).

LT PE

This is the relationship between the price (P) and the estimated long-term future earnings (E LT).

LT Growth

This is the estimated annual growth rate of future earnings, normally projected over the next two to three years.

MT Tech Trend

The MT Tech Trend indicates the current trend, positive 🟢 or negative 🟡, and the Tech Reverse indicates up to which price this trend will remain valid.

When a price falls to 1.75% above or below the Tech Reverse, the MT Tech Trend is considered neutral 🟢.

Once the price breaks out of the +1.75% neutral zone, the MT Tech Trend will change to positive.

The symbol 🟢 indicates that the previous MT Tech Trend was positive.

The symbol 🟡 indicates that the previous MT Tech Trend was negative.

4wk (Rel) Perf.

This figure measures the performance of a stock relative to its national or regional index (compared to four weeks ago). As for an Index, it measures the net performance over 4 weeks.

Bad News Factor

To determine the "Bad News Factor" we analyze a stock's declines in rising markets. In this purely objective analysis, the actual reasons for a stock's behavior are not important. If a stock price falls while its relative index goes up, it can be assumed that the stock's performance has been affected by bad news - hence the name, "Bad News Factor".

Here a stock's movements are measured on a bi-weekly basis, during a sliding 52 week period. Every time a stock drops while its reference index rises, the difference is calculated in %, integrated into a yearly average and expressed in basis points.

The higher the "Bad News Factor," the more a stock has proven to be sensitive to bad news. The lower the "Bad News Factor," the less the stock has proven to be sensitive to bad news.

Bear Market Factor

To determine the "Bear Market Factor" we analyze a stock's price movements in declining markets.

This is the analysis of the movements, in a bi-weekly intervals, during a sliding 52 week period.

The higher the "Bear Market Factor," the greater the probability a stock would drop when its relative index drops.

A "Bear Market Factor" that is strongly negative means the stock has been more resistant to losses in declining markets.

Sensitivity

Stock price developments are generally volatile and contain high risks that can result in a total loss. Based on a their historical behaviour, stocks are classified by sensitivity level. These sensitivity levels have to be considered solely in relative historical comparison to other stocks. Please note that even "Low Sensitivity" stocks are equities and therefore high risk investments that can lose up to all of their value, and that past performance is no indication of current or future performance.

"Sensitivity" is determined by measuring the "Bear Market Factor" and the "Bad News Factor" against its benchmark.

There are three grades of sensitivity levels:

- Low Sensitivity: The sensitivity indicators fall below the world reference average.
- Moderate Sensitivity: The sensitivity indicators are situated higher than the world reference average, but lower than standard deviation.
- High Sensitivity: The sensitivity indicators are at levels higher than standard deviation.

Volatility 12 M

Volatility measures the magnitude of upwards and downwards movements of a stock or index. The volatility 12 M shows the average volatility over the last 12 months.

% of Stocks in Uptrend

This is the percentage of stocks in a given list that have a positive Medium Term Technical Trend. If, for example, the aggregate of Technology / World, (which is made up of 458 stocks) has 8% "of stocks in Uptrend," it means that 38 of the stocks within that aggregate have a positive Medium Term Technical Trend.

Beta

Beta is often used as a measure of sensitivity. Where a Beta is greater than 100, the stock is more volatile than its reference index.

Correlation

Correlation is the degree of similarity (in %) in which a stock fluctuates in relation to its reference index.

Disclaimer:

This report is provided for your personal information only, and does not constitute or contain any solicitation, financial advice, or offer to buy or sell any kind of securities. This report was based on sources that we consider reliable, but we do not warrant the accuracy and exhaustiveness of the information, opinions and quotes provided. Past performance is no guarantee of future results.

More information: www.thescreener.com/en/wc/methodology.htm

Earnings forecasts provided by THOMSON REUTERS.